Latest news with #BIO-EuropeSpring
Yahoo
19-03-2025
- Business
- Yahoo
High Growth Tech Stocks In Europe March 2025
In March 2025, the European market is navigating a complex landscape characterized by concerns over U.S. trade tariffs, economic growth uncertainties, and fluctuating monetary policies. Despite these challenges, high growth tech stocks in Europe continue to attract attention as investors seek opportunities that align with resilient business models and innovative capabilities capable of weathering broader market volatility. Name Revenue Growth Earnings Growth Growth Rating Elicera Therapeutics 63.53% 97.24% ★★★★★★ Pharma Mar 24.24% 40.82% ★★★★★★ CD Projekt 30.55% 39.06% ★★★★★★ Yubico 20.88% 26.53% ★★★★★★ Xbrane Biopharma 73.73% 139.21% ★★★★★★ XTPL 97.45% 117.95% ★★★★★★ Devyser Diagnostics 26.50% 94.65% ★★★★★★ Elliptic Laboratories 49.76% 88.21% ★★★★★★ Ascelia Pharma 46.09% 66.93% ★★★★★★ Skolon 29.71% 91.18% ★★★★★★ Click here to see the full list of 243 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €228.43 million. Operations: Oryzon Genomics focuses on the discovery and development of epigenetics-based therapeutics targeting cancer and CNS disorders. As a clinical stage biopharmaceutical company, it does not currently report revenue from product sales. Oryzon Genomics is making significant strides in the biotech sector, particularly in precision medicine for psychiatric and neurodevelopmental disorders. Recently, Oryzon announced positive outcomes from Phase IIa trials of vafidemstat in various psychiatric conditions and is advancing this promising drug into a Phase III trial for Borderline Personality Disorder, with FDA discussions set for the first half of 2025. This progression underscores Oryzon's commitment to addressing unmet medical needs through innovative therapies. Furthermore, the company's recent presentation at BIO-Europe Spring and its continuous R&D efforts highlight its potential to impact future treatments significantly. With an annual revenue growth forecast at 52% and earnings expected to surge by approximately 54%, Oryzon exemplifies a dynamic player within Europe's high-growth tech landscape. Navigate through the intricacies of Oryzon Genomics with our comprehensive health report here. Gain insights into Oryzon Genomics' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: BioGaia AB (publ) is a healthcare company that develops and sells probiotic products globally, with a market capitalization of SEK11.83 billion. Operations: The company generates revenue primarily from its Pediatrics segment, contributing SEK 1.09 billion, followed by the Adult Health segment at SEK 321.29 million. BioGaia, a Swedish biotech firm, has recently demonstrated robust financial performance with its Q4 sales surging by 23% to SEK 365 million and operating profit increasing by 28% to SEK 103 million. This growth is underpinned by an annual revenue increase of 10.9% and earnings growth forecasted at 15% per year, outpacing the Swedish market averages significantly. The company's strategic move to directly manage its operations in France reflects a proactive approach in tapping into the growing health-conscious consumer base there, leveraging its reputation for high-quality probiotics. These developments suggest BioGaia is effectively capitalizing on niche market trends while maintaining strong financial health. Click here to discover the nuances of BioGaia with our detailed analytical health report. Assess BioGaia's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Telefonaktiebolaget LM Ericsson (publ) is a company that offers mobile connectivity solutions to communications service providers, enterprises, and the public sector, with a market capitalization of approximately SEK278.13 billion. Operations: Ericsson generates revenue primarily from its Networks segment, which accounts for SEK158.21 billion, followed by Cloud Software and Services at SEK62.64 billion, and Enterprise at SEK24.86 billion. The company's business model focuses on providing mobile connectivity solutions to various sectors including communications service providers and enterprises. Telefonaktiebolaget LM Ericsson, a stalwart in telecommunications, is making significant strides in leveraging advanced technologies like AI and 5G. With its recent strategic alliances, including a notable partnership with Volvo Group and Bharti Airtel to explore Extended Reality and Digital Twin technologies, Ericsson is at the forefront of industrial digital transformation. This collaboration aims to enhance manufacturing processes and workforce training through the integration of 5G's ultra-low latency capabilities. Financially, Ericsson has demonstrated robust growth with a notable increase in earnings forecasted at an impressive 47% annually. Despite moderate revenue growth projections at 1.9% per year, the company's commitment to R&D remains strong, ensuring sustained innovation and competitiveness in the high-tech industry landscape. Dive into the specifics of Telefonaktiebolaget LM Ericsson here with our thorough health report. Review our historical performance report to gain insights into Telefonaktiebolaget LM Ericsson's's past performance. Click here to access our complete index of 243 European High Growth Tech and AI Stocks. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BME:ORY OM:BIOG B and OM:ERIC B. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Associated Press
17-03-2025
- Business
- Associated Press
Enveric Biosciences Participating in BIO-Europe Spring®
Enveric Biosciences, Inc. (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring ®, which is being held in Milan, Italy, March 17-19, 2025. During the Spring partnering event, members of Enveric's management team are conducting one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. 'We anticipate a highly productive meeting at BIO-Europe Spring as we continue to garner interest in our strategic approach to developing neuroplastogenic molecules, led by EB-003, for the treatment of underserved mental health conditions. Our ongoing discussions with leaders in the pharmaceutical industry clearly indicate that eliminating or substantially reducing the hallucinatory effect common to N,N-Dimethyltryptamine (DMT), mescaline and related analogs will be key to commercial success,' said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric. About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 [email protected] Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 INDUSTRY KEYWORD: MENTAL HEALTH HEALTH GENERAL HEALTH RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Enveric Biosciences, Inc. Copyright Business Wire 2025. PUB: 03/17/2025 01:40 PM/DISC: 03/17/2025 01:40 PM
Yahoo
24-02-2025
- Business
- Yahoo
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ('Bright Minds,' 'BMB' or the 'Company') (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and select members of senior management, will participate in three healthcare conferences, as follows: TD Cowen 45th Annual Health Care Conference, Boston Monday, March 3, 2025, at 1:10pm ETJoin the webcast Leerink Partners Global Healthcare Conference, MiamiWednesday, March 12, 2025 (1x1 meetings) BIO-Europe Spring, MilanMarch 17-19, 2025 The live and archived webcasts will be accessible from the Company's website at under Events and Presentation. The replay of the webcast will be accessible for 90 days. About Bright Minds Biosciences Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives. Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry. Contact Information Alex VasilkevichChief Operating OfficerBright Minds Biosciences Inc.T: 414-731-6422E: alex@ Investor RelationsLisa M. WilsonT: 212-452-2793E: lwilson@
